Search clinical trials for: Placebo to Omarigliptin

Total 60028 results

Merck Sharp & Dohme LLC

Completed

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D)
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

Type 2 Diabetes Mellitus | Chronic Renal Insufficiency
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
British University In Egypt

Completed

Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers

Diabetes Mellitus, Type 2

Egypt
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, Austria, Germany, United States, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (ACI)

Knee Cartilage Lesion

Austria
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
Bayer

Recruiting

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (SIRIUS)

Thrombolysis | Symptomatic Proximal Deep Vein Thrombosis

Belgium, France, Italy, Netherlands, Canada, Germany
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Asthma

United States, Belgium, Germany, Israel, Argentina, France, Denmark, Slovakia
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Active, not recruiting

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (SANTE)

Stillbirths and Infant Mortality

Mali
Texas Tech University
EHP Labs

Completed

Metabolic Effects of a Thermogenic Ready-to-drink Beverage

Metabolism | Metabolic Rate

United States
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Cardior Pharmaceuticals GmbH

Active, not recruiting

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Myocardial Infarction, Acute | Heart Failure, Left Sided

Netherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
Bayer

Completed

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

Hypertension | Chronic Kidney Disease

Germany, Bulgaria
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Not yet recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
Novartis Pharmaceuticals

Terminated

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers | Part 2 - Patients With Hypertension

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
Harvard University

Withdrawn

Mindfulness Intervention and Symptom Variability in Hearing

Hearing Loss

United States
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon

3

Subscribe